Modulating the PD-1/PD-L1 pathway involves targeted efforts to disrupt the communication between PD-1 receptors on T-cells and PD-L1 ligands, which are frequently exaggerated on cancer cells and within the tumor microenvironment. Here, CD274 is linked to neoplasm.